{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:05:25Z","timestamp":1786993525325,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015394","name":"American Society for Transplantation and Cellular Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011619","name":"Society for Immunotherapy of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.02.054","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:24:18Z","timestamp":1772126658000},"page":"802-814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1302-9577","authenticated-orcid":false,"given":"Kedar","family":"Kirtane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1839-3194","authenticated-orcid":false,"given":"Michael","family":"Kalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocky","family":"Billups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-5448","authenticated-orcid":false,"given":"Aude G.","family":"Chapuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2691-3409","authenticated-orcid":false,"given":"Brian","family":"Gastman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-7704","authenticated-orcid":false,"given":"John","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-7892","authenticated-orcid":false,"given":"Patrick J.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4725-2531","authenticated-orcid":false,"given":"Emily L.","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6971-8465","authenticated-orcid":false,"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy V.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nathenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Rivi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanjan","family":"Sikder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Tendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason","family":"Luke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin E.","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.02.054_bib0001","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.948125","article-title":"A review of CAR T cells and adoptive T-cell therapies in lymphoid and solid organ malignancies","volume":"31","author":"Parums","year":"2025","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jtct.2026.02.054_bib0002","series-title":"CAR T and Beyond: The Expanding Pipeline and Promise of Cell Therapies","author":"Qiu","year":"2025"},{"issue":"6753","key":"10.1016\/j.jtct.2026.02.054_bib0003","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtct.2026.02.054_bib0005","article-title":"Cell-based immunotherapies for solid tumors: advances, challenges, and future directions","volume":"15","author":"Zhao","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2026.02.054_bib0006","series-title":"Package Insert TECELRA: U.S. Food and Drug Administration","author":"Adaptimmune","year":"2024"},{"key":"10.1016\/j.jtct.2026.02.054_bib0007","series-title":"Package Insert\u2014Amtagvi: U.S. Food and Drug Administration","year":"2024"},{"issue":"5","key":"10.1016\/j.jtct.2026.02.054_bib0008","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.054_bib0009","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.054_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0011","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.054_bib0012","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.054_bib0013","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.054_bib0014","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.054_bib0015","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.054_bib0016","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"Rejeski","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.054_bib0017","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2026.02.054_bib0018","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.054_bib0019","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement_1","key":"10.1016\/j.jtct.2026.02.054_bib0020","doi-asserted-by":"crossref","first-page":"i50","DOI":"10.1093\/neuonc\/noad073.192","article-title":"IMMU-05. Tumor inflammation-associated neurotoxicity (tian): a toxicity syndrome in patients treated with immunotherapy for central nervous system tumors","volume":"25","author":"Mahdi","year":"2023","journal-title":"Neuro-oncology"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.054_bib0021","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jtct.2025.06.017","article-title":"Assessing physical function in transplantation and CAR-T recipients: expert recommendations from the survivorship, aging and biobehavioral special interest groups of ASTCT","volume":"31","author":"Farhan","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.054_bib0022","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jtct.2025.06.026","volume":"31","author":"Kennedy","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.054_bib0023","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jtct.2025.06.030","article-title":"Assessing quality of life and symptoms in transplantation and CAR-T recipients: expert panel recommendations from the Survivorship Special Interest Group of ASTCT","volume":"31","author":"Banerjee","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.054_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.02.017","article-title":"Infections in patients with solid tumors undergoing adoptive cellular therapy","author":"Avutu","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.054_bib0025","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.054_bib0026","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/bloodadvances.2023010401","article-title":"A robust quality infrastructure is key to safe and effective delivery of immune effector cells: how FACT-finding can help","volume":"8","author":"Curran","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.054_bib0027","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jtct.2025.05.012","article-title":"Setting up a chimeric antigen receptor T cell therapy program: a framework for delivery from the worldwide network for blood & marrow transplantation","volume":"31","author":"Ahmed","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"10.1016\/j.jtct.2026.02.054_bib0028","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","article-title":"Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: a SEER-Medicare data analysis","volume":"9","author":"Chung","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.02.054_bib0029","series-title":"Managing the Challenges of Paying for Gene Therapy: Strategies for Market Action and Policy Reform","author":"Phares","year":"2024"},{"issue":"9","key":"10.1016\/j.jtct.2026.02.054_bib0030","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jtct.2025.06.028","article-title":"Improving patient access through value-based CAR T delivery: examples using a micro-costing tool","volume":"31","author":"Shafey","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0031","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jcyt.2022.07.011","article-title":"A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan blood and tissue bank experience","volume":"25","author":"Fernandez-Sojo","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.02.054_bib0032","series-title":"Vitalant Launches National Service Hubs to Expand Patient Access to Cell and Gene Therapies: Discover Pharma","author":"Laws","year":"2025"},{"key":"10.1016\/j.jtct.2026.02.054_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076625","article-title":"Illness trajectories of incurable solid cancers","volume":"384","author":"Geijteman","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.054_bib0034","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41585-025-01088-6","article-title":"The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers","volume":"23","author":"Potez","year":"2026","journal-title":"Nat Rev Urol"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.054_bib0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2023.01.021","volume":"29","author":"Nikiforow","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.054_bib0036","series-title":"Long Term Follow-Up After Administration of Human Gene Therapy Products: Guidance for Industry","year":"2020"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.054_bib0037","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","article-title":"Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies","volume":"31","author":"Jadlowsky","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.054_bib0038","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0039","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2022015728","article-title":"Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs","volume":"140","author":"Steffin","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymthe.2017.12.003","article-title":"Absence of replication-competent retrovirus in vectors, T cell products, and patient follow-up samples","volume":"26","author":"Lyon","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2017.12.004","article-title":"Seek and you will not find: ending the hunt for replication-competent retroviruses during human gene therapy","volume":"26","author":"Heslop","year":"2018","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0042","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ymthe.2017.10.012","article-title":"Retroviral and lentiviral safety analysis of gene-modified T cell products and infused HIV and oncology patients","volume":"26","author":"Marcucci","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.02.054_bib0043","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.omtm.2018.08.006","article-title":"Screening clinical cell products for replication competent retrovirus: the national gene vector biorepository experience","volume":"10","author":"Cornetta","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0044","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ymthe.2017.09.008","article-title":"Absence of replication-competent lentivirus in the clinic: analysis of infused T cell products","volume":"26","author":"Cornetta","year":"2018","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.054_bib0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ymthe.2022.12.006","article-title":"Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: no evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials","volume":"31","author":"Cornetta","year":"2023","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101186","article-title":"Long-term stability of clinical-grade lentiviral vectors for cell therapy","volume":"32","author":"Jadlowsky","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtct.2026.02.054_bib0047","unstructured":"U.S Food and Drug Administration. Vitro Companion Diagnostic Devices: Guidance for Industry and Food and Drug Administration Staff. 2014.https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/in-vitro-companion-diagnostic-devices. Accessed February 19, 2026."},{"issue":"1","key":"10.1016\/j.jtct.2026.02.054_bib0048","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jama.2025.21721","article-title":"Advancing CAR T-cell therapy: evidence-based trial design for chimeric antigen receptor T-cell therapy in oncology","volume":"335","author":"Mahat","year":"2026","journal-title":"JAMA"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:57:26Z","timestamp":1782745046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726001570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666636726001570"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.054","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing Cell Therapies for Solid Tumors: A Pathway to Overcome Biological, Operational, and Regulatory Hurdles","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}